$GRTSQ
Gritstone bio, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024096211 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $921.0K
YoY Change -52.89%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.698M
YoY Change 14.62%
% of Gross Profit
Research & Development $20.81M
YoY Change -32.8%
% of Gross Profit
Depreciation & Amortization $1.604M
YoY Change -15.89%
% of Gross Profit
Operating Expenses $28.51M
YoY Change -24.35%
Operating Profit -$27.59M
YoY Change -22.78%
Interest Expense $1.304M
YoY Change 32.39%
% of Operating Profit
Other Income/Expense, Net $4.805M
YoY Change -21940.91%
Pretax Income -$23.40M
YoY Change -33.64%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$23.40M
YoY Change -33.64%
Net Earnings / Revenue -2540.28%
Basic Earnings Per Share -$0.16
Diluted Earnings Per Share -$0.16
COMMON SHARES
Basic Shares Outstanding 118.1M 108.6M
Diluted Shares Outstanding 143.3M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $55.71M
YoY Change -51.36%
Cash & Equivalents $50.90M
Short-Term Investments $4.812M
Other Short-Term Assets $467.0K
YoY Change -34.96%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $60.71M
YoY Change -50.39%
LONG-TERM ASSETS
Property, Plant & Equipment $12.53M
YoY Change -38.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.304M
YoY Change -32.17%
Total Long-Term Assets $81.83M
YoY Change -18.37%
TOTAL ASSETS
Total Short-Term Assets $60.71M
Total Long-Term Assets $81.83M
Total Assets $142.5M
YoY Change -35.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.132M
YoY Change -16.1%
Accrued Expenses $856.0K
YoY Change -41.05%
Deferred Revenue $698.0K
YoY Change -75.23%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.90M
YoY Change 8.1%
LONG-TERM LIABILITIES
Long-Term Debt $40.51M
YoY Change 36.28%
Other Long-Term Liabilities $1.117M
YoY Change 180.65%
Total Long-Term Liabilities $41.62M
YoY Change 38.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.90M
Total Long-Term Liabilities $41.62M
Total Liabilities $120.4M
YoY Change 6.45%
SHAREHOLDERS EQUITY
Retained Earnings -$723.3M
YoY Change 22.53%
Common Stock $24.00K
YoY Change 9.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.19M
YoY Change
Total Liabilities & Shareholders Equity $142.5M
YoY Change -35.97%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$23.40M
YoY Change -33.64%
Depreciation, Depletion And Amortization $1.604M
YoY Change -15.89%
Cash From Operating Activities -$26.81M
YoY Change -13.41%
INVESTING ACTIVITIES
Capital Expenditures $32.00K
YoY Change -98.14%
Acquisitions
YoY Change
Other Investing Activities -$853.0K
YoY Change -103.24%
Cash From Investing Activities -$885.0K
YoY Change -103.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 35.63M
YoY Change 3403.74%
NET CHANGE
Cash From Operating Activities -26.81M
Cash From Investing Activities -885.0K
Cash From Financing Activities 35.63M
Net Change In Cash 7.937M
YoY Change -248.24%
FREE CASH FLOW
Cash From Operating Activities -$26.81M
Capital Expenditures $32.00K
Free Cash Flow -$26.84M
YoY Change -17.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001656634
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38663
dei Entity Registrant Name
EntityRegistrantName
Gritstone bio, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4859534
dei Entity Address Address Line1
EntityAddressAddressLine1
5959 Horton Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
871-6100
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
GRTS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
118109074
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50900000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62986000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
4812000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
16288000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
1274000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
2299000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3724000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5862000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
60710000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
87435000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4695000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5290000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12527000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17281000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
64001000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
66839000
CY2024Q2 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
609000
CY2023Q4 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
924000
CY2024Q2 us-gaap Assets
Assets
142542000
CY2023Q4 us-gaap Assets
Assets
177769000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4132000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3819000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5272000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9357000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
856000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1213000
CY2024Q2 grts Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3002000
CY2023Q4 grts Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3696000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7159000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6904000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
698000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2350000
CY2024Q2 grts Warrant Liability
WarrantLiability
2782000
CY2023Q4 grts Warrant Liability
WarrantLiability
0
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
23901000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27339000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1117000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
709000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
54829000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
57727000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40506000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40144000
CY2024Q2 us-gaap Liabilities
Liabilities
120353000
CY2023Q4 us-gaap Liabilities
Liabilities
125919000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
117787732
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
117787732
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97585415
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97585415
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
24000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
22000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
745510000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
711386000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-723342000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-659561000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
22189000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
51850000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
142542000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
177769000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
921000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1955000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2663000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4397000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20811000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30967000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53852000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61481000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7698000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6716000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16200000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13461000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
28509000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
37683000
us-gaap Operating Expenses
OperatingExpenses
70052000
us-gaap Operating Expenses
OperatingExpenses
74942000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-27588000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-35728000
us-gaap Operating Income Loss
OperatingIncomeLoss
-67389000
us-gaap Operating Income Loss
OperatingIncomeLoss
-70545000
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
691000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1479000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1403000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3157000
CY2024Q2 us-gaap Interest Expense
InterestExpense
1304000
CY2023Q2 us-gaap Interest Expense
InterestExpense
985000
us-gaap Interest Expense
InterestExpense
2600000
us-gaap Interest Expense
InterestExpense
1828000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4805000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4805000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-23396000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-35256000
us-gaap Net Income Loss
NetIncomeLoss
-63781000
us-gaap Net Income Loss
NetIncomeLoss
-69238000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-2000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-73000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-6000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-45000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23398000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35329000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63787000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-69283000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.6
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.6
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
143296662
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
143296662
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114929523
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114929523
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
130843943
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
130843943
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114676261
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114676261
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
13964000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-2000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2024Q2 grts Issuance Of Common Stock For Warrant Exercises Value
IssuanceOfCommonStockForWarrantExercisesValue
40000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
132000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3467000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-23396000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
22189000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
140878000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
450000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2940000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-73000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-35256000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
109567000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
51850000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-6000
grts Tax Payments Related To Shares Withheld For Vested Restricted Stock Units
TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits
788000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
61000
grts Issuance Of Common Stock For Warrant Exercises Value
IssuanceOfCommonStockForWarrantExercisesValue
40000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
132000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6713000
us-gaap Net Income Loss
NetIncomeLoss
-63781000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
22189000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
170781000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-45000
grts Tax Payments Related To Shares Withheld For Vested Restricted Stock Units
TaxPaymentsRelatedToSharesWithheldForVestedRestrictedStockUnits
742000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
450000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5831000
us-gaap Net Income Loss
NetIncomeLoss
-69238000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
109567000
us-gaap Net Income Loss
NetIncomeLoss
-63781000
us-gaap Net Income Loss
NetIncomeLoss
-69238000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3346000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3706000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
123000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1797000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
770000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
637000
us-gaap Share Based Compensation
ShareBasedCompensation
6713000
us-gaap Share Based Compensation
ShareBasedCompensation
5831000
grts Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
6614000
grts Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
6762000
grts Impairment Of Property Plant And Equipment
ImpairmentOfPropertyPlantAndEquipment
-1483000
grts Impairment Of Property Plant And Equipment
ImpairmentOfPropertyPlantAndEquipment
-21000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4805000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2138000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1608000
grts Increase Decrease In Deposit And Other Assets Noncurrent
IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
-315000
grts Increase Decrease In Deposit And Other Assets Noncurrent
IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
-3014000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
59000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1295000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4085000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2179000
grts Increase Decrease In Accrued And Other Liabilities Non Current
IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
-381000
grts Increase Decrease In Accrued And Other Liabilities Non Current
IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
-2253000
grts Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-694000
grts Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-1301000
grts Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-6295000
grts Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-12256000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1652000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2313000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60378000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-71053000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3081000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
17814000
grts Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
14537000
grts Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
66867000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
137000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
175000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3288000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11418000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45765000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
9962000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
2210000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
2496000
grts Payments Of Financing Lease
PaymentsOfFinancingLease
124000
grts Payments Of Financing Lease
PaymentsOfFinancingLease
119000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
788000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
742000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35254000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9664000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13706000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15624000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70575000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64765000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56869000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49141000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
33000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
692000
us-gaap Interest Paid Net
InterestPaidNet
1764000
us-gaap Interest Paid Net
InterestPaidNet
1073000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
392000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
16000
grts Assets Acquired Under Leasing Obligations
AssetsAcquiredUnderLeasingObligations
748000
grts Assets Acquired Under Leasing Obligations
AssetsAcquiredUnderLeasingObligations
59320000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-23400000
us-gaap Net Income Loss
NetIncomeLoss
-63800000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-35300000
us-gaap Net Income Loss
NetIncomeLoss
-69200000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60400000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-71100000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-723300000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-659600000
CY2024Q2 grts Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
55700000
grts Company Planned Operation
CompanyPlannedOperation
P12M
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50900000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62986000
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
1274000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
2299000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4695000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5290000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
56869000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
70575000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, determining the fair value of assets and liabilities, the fair value of right-of-use assets and lease liabilities, stock-based compensation expense, warrant liability, and including those related to revenue recognition, including but not limited to, transaction price and progress toward completion of performance obligation under the Company's contracts with customers. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the condensed consolidated balance sheets. As of June 30</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has no off-balance sheet concentrations of credit risk.</span></p>
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
44681000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
44678000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
62262000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
62265000
grts Marketable Securities Realized Gain Loss Description
MarketableSecuritiesRealizedGainLossDescription
no material realized gains or losses
CY2023 grts Marketable Securities Realized Gain Loss Description
MarketableSecuritiesRealizedGainLossDescription
no material realized gains or losses
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
grts Period Of Unrealized Loss Position
PeriodOfUnrealizedLossPosition
12 months or greater
grts Fair Value Measurement Level1 To Level2 Transfers
FairValueMeasurementLevel1ToLevel2Transfers
0
CY2023 grts Fair Value Measurement Level1 To Level2 Transfers
FairValueMeasurementLevel1ToLevel2Transfers
0
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
47541000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
49681000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
35029000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
32415000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12527000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17281000
CY2024Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1600000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3300000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1900000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3700000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3206000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
4439000
us-gaap Operating Lease Cost
OperatingLeaseCost
6427000
us-gaap Operating Lease Cost
OperatingLeaseCost
6603000
CY2024Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
13000
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
us-gaap Short Term Lease Cost
ShortTermLeaseCost
31000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2024Q2 us-gaap Lease Cost
LeaseCost
3219000
CY2023Q2 us-gaap Lease Cost
LeaseCost
4439000
us-gaap Lease Cost
LeaseCost
6458000
us-gaap Lease Cost
LeaseCost
6603000
us-gaap Operating Lease Payments
OperatingLeasePayments
6295000
us-gaap Operating Lease Payments
OperatingLeasePayments
12256000
grts Assets Acquired Under Leasing Obligations
AssetsAcquiredUnderLeasingObligations
748000
grts Assets Acquired Under Leasing Obligations
AssetsAcquiredUnderLeasingObligations
59320000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y10M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y7M6D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.102
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.099
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
6546000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
11420000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
10376000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
10466000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
10732000
CY2024Q2 grts Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
41615000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
91155000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
29167000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
61988000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7159000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
54829000
CY2024Q2 grts Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
2285000
CY2023Q4 grts Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
3904000
CY2024Q2 grts Collaboration Receivable
CollaborationReceivable
39000
CY2023Q4 grts Collaboration Receivable
CollaborationReceivable
14000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
453000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
940000
CY2024Q2 grts Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
156000
CY2023Q4 grts Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
217000
CY2024Q2 grts Facilities Related Deposits
FacilitiesRelatedDeposits
324000
CY2023Q4 grts Facilities Related Deposits
FacilitiesRelatedDeposits
9000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
467000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
778000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3724000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5862000
CY2024Q2 us-gaap Security Deposit
SecurityDeposit
609000
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
924000
CY2024Q2 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
609000
CY2023Q4 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
924000
CY2024Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
40000000
CY2024Q2 grts Final Fee
FinalFee
2300000
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-1794000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
40506000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
8457000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
18030000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour
13513000
CY2024Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
40000000
CY2024Q2 grts License Revenue
LicenseRevenue
0
grts License Revenue
LicenseRevenue
0
CY2023Q2 grts License Revenue
LicenseRevenue
0
grts License Revenue
LicenseRevenue
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
117787732
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
117787732
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97585415
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97585415
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of the Company’s common stock are entitled to one vote per share.
CY2022Q1 grts Maximum Securities Covered Under Registration Agreement
MaximumSecuritiesCoveredUnderRegistrationAgreement
250000000
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
51481634
CY2024Q2 grts Class Of Warrant Or Right Warrants Exercised
ClassOfWarrantOrRightWarrantsExercised
4009399
grts Class Of Warrant Or Right Warrants Exercised
ClassOfWarrantOrRightWarrantsExercised
4009399
CY2023Q2 grts Class Of Warrant Or Right Warrants Exercised
ClassOfWarrantOrRightWarrantsExercised
2859971
grts Class Of Warrant Or Right Warrants Exercised
ClassOfWarrantOrRightWarrantsExercised
2859971
grts Issuance Of Common Stock For Warrant Exercises Share
IssuanceOfCommonStockForWarrantExercisesShare
2849405
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
6186925
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7273461
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.5
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M3D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
264000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
3903416
grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted
8947004
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7015522
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.74
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
30797
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.99
grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled
2403755
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1512706
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.84
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3547092
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12745480
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.78
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M28D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
14000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
5838765
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
7.55
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y9M3D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
14000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
12139168
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.9
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
14000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4800000
grts Stock Based Compensation Expense And Awards Granted To Non Employees
StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees
400000
grts Stock Based Compensation Expense And Awards Granted To Non Employees
StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees
300000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3088970
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
814462
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
826642
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
3.28
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
461245
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
3.01
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2615545
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.99
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3467000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2940000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6713000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5831000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-23396000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-35256000
us-gaap Net Income Loss
NetIncomeLoss
-63781000
us-gaap Net Income Loss
NetIncomeLoss
-69238000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
143296662
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
143296662
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114929523
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114929523
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
130843943
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
130843943
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114676261
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114676261
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.6
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.6
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38029406
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11053263
CY2024Q1 grts Reduction In Workforce
ReductionInWorkforce
0.40
CY2024Q1 grts Severance And Other Costs
SeveranceAndOtherCosts
3900000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
0

Files In Submission

Name View Source Status
0000950170-24-096211-index-headers.html Edgar Link pending
0000950170-24-096211-index.html Edgar Link pending
0000950170-24-096211.txt Edgar Link pending
0000950170-24-096211-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
grts-20240630.htm Edgar Link pending
grts-20240630.xsd Edgar Link pending
grts-ex10_1.htm Edgar Link pending
grts-ex31_1.htm Edgar Link pending
grts-ex31_2.htm Edgar Link pending
grts-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
grts-20240630_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable